These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 39171895)

  • 1. Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole-Body Physiologically Based Pharmacokinetic Model.
    Liu T; Mu R; Liu X
    J Clin Pharmacol; 2024 Aug; ():. PubMed ID: 39171895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery.
    Porat D; Dukhno O; Vainer E; Cvijić S; Dahan A
    Mol Pharm; 2022 Aug; 19(8):2922-2936. PubMed ID: 35759355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice.
    Dridi D; Ben-Attia M; Sani M; Djebli N; Sauvage FL; Boughattas NA
    Chronobiol Int; 2008 Jul; 25(4):533-47. PubMed ID: 18622814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.
    Zhang Y; Zhao S; Wang C; Zhou P; Zhai S
    Front Pharmacol; 2021; 12():636097. PubMed ID: 33815119
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects.
    Luo X; Zhang Z; Mu R; Hu G; Liu L; Liu X
    Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
    Gupta S; Banfield C; Kantesaria B; Marino M; Clement R; Affrime M; Batra V
    Clin Ther; 2001 Mar; 23(3):451-66. PubMed ID: 11318079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers.
    Noehr-Jensen L; Damkier P; Bidstrup TB; Pedersen RS; Nielsen F; Brosen K
    Eur J Clin Pharmacol; 2006 Jun; 62(6):437-45. PubMed ID: 16770647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
    Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years.
    Salmun LM; Herron JM; Banfield C; Padhi D; Lorber R; Affrime MB
    Clin Ther; 2000 May; 22(5):613-21. PubMed ID: 10868558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.
    Affrime M; Banfield C; Gupta S; Cohen A; Boutros T; Thonoor M; Cayen M
    Clin Pharmacokinet; 2002; 41 Suppl 1():21-8. PubMed ID: 12169043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults.
    Gupta SK; Kantesaria B; Banfield C; Wang Z
    Br J Clin Pharmacol; 2007 Aug; 64(2):174-84. PubMed ID: 17324243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
    Barecki ME; Casciano CN; Johnson WW; Clement RP
    Drug Metab Dispos; 2001 Sep; 29(9):1173-5. PubMed ID: 11502723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic profile of desloratadine in healthy adults, including elderly.
    Affrime M; Gupta S; Banfield C; Cohen A
    Clin Pharmacokinet; 2002; 41 Suppl 1():13-9. PubMed ID: 12169042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain histamine H
    Nakamura T; Hiraoka K; Harada R; Matsuzawa T; Ishikawa Y; Funaki Y; Yoshikawa T; Tashiro M; Yanai K; Okamura N
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00499. PubMed ID: 31338198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of Desloratadine and Its Metabolite 3-OH Desloratadine in Human Plasma by LC-MS/MS].
    Zhang K; Zhang XQ; Lu W; Xie HR; He L; Jiang XH; Wang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):783-7, 804. PubMed ID: 26619557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans.
    Mu RJ; Liu TL; Liu XD; Liu L
    Acta Pharmacol Sin; 2024 Aug; 45(8):1752-1764. PubMed ID: 38570601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.